Banner Welcome
Sign Up and Receive $350 off your Purchase
Stay in the loop with the latest news, updates and resources from Exo. Join and we’ll send you $350 off your purchase of an Iris from Exo’s store!
EXO
FDA Cleared | Available on Exo IrisTM
FDA Cleared | Available on Exo IrisTM

Cardiac & Lung AI

Reduce the threshold for answers

It’s time for a new approach to heart failure

Heart failure affects more than 64 million people worldwide¹. In the United States alone, over 6.7 million have heart failure² and that number is expected to increase to 8 million with annual healthcare spending ballooning to $240 billion by 2030³.

  • Leading cause of hospitalizations in people over 65 years⁴ with an excess of 1 million admissions per year⁵
  • 23% of patients are readmitted within 30 days⁶
  • Average HF-related admission cost is $14,000⁷

Healthcare providers need innovative solutions to detect and treat heart failure earlier at the point of care – hospital, clinic or home.

Accelerating diagnosis

Echocardiography is the cornerstone of heart failure diagnosis⁸. Today, expert sonographers evaluate this common and costly disease, then cardiologists interpret the tests. What if technology could bring this critical evaluation to the point of care, at a lower cost, and give clinicians reliable answers? Exo’s AI-enabled point-of-care ultrasound (POCUS) has been designed to bring this information from a few to everyone. Get to answers immediately, accelerating diagnosis and improving patient care.

Say hello to Exo's Cardiac and Lung AI, now on Exo Iris.

Reliable answers fast

Is your patient’s dyspnea (difficulty breathing) caused by the heart or the lungs? Is your heart failure patient ready for discharge? Is your patient progressing with therapy treatment?

With Exo AI, you can quickly scan your patient’s heart and lungs to get the answers you need. Reduce diagnostic error and accelerate patient care pathways to treatment or discharge.

Cardiac AI

With Exo’s Cardiac AI, you can measure left ventricular ejection fraction (LVEF) and stroke volume in a few heartbeats in both parasternal long axis (PLAX) and apical four-chamber (A4C) views, making it easier than ever for POCUS users to get to answers.

Lung AI

With Lung AI, you can determine the presence or absence of B-lines reliably in seconds.

5-star answers for 3-star images

Whether you’re an early POCUS user or a seasoned expert, Exo’s Cardiac and Lung AI can simplify the process of obtaining and interpreting images. Built on data from over 100,000 images from POCUS users in emergency rooms and critical care units, our AI is developed around real-world images and not perfect images performed in a cardiac lab.

What does all this mean?

It means you don’t need the perfect scan to get an answer.

Image Quality

Image Quality

Image Quality

Image Quality

Image Quality

Image Quality

Unrelenting performance

Exo's Cardiac and Lung AI stands out for its exceptional performance, validated through our rigorous internal qualification process in compliance with FDA regulations. We’ve developed and tested our AI using over 100,000 scans from various patient populations and from various diagnostic types. Not getting the perfect image is not a problem.

Our AI validation comes from diverse demographics (gender, ethnicity, location), BMI and health conditions (heart failure with reduced ejection fraction, coronary artery disease and cardiomyopathy). This unique and rigorous approach ensures our AI achieves excellence across a spectrum of scenarios.

Cardiac AI

High Reliability

Excellent agreement with LVEF measurements done by experts (cardiologists or experienced echosonographers) with an Inter Class Correlation (ICC) score of 0.91

High Accuracy

AI matches or exceeds accuracy seen in expert measurements with a Root-mean square error (RMSE) of 8.82% compared to an inter-observer variability between expert observers of 10-14%

Lung AI

High Reliability

Excellent agreement with B-lines done by experts (experienced echosonographers) with an Inter Class Correlation (ICC) score of 0.93

High Accuracy

AI matches or exceeds accuracy seen in expert measurements for the presence/absence of A-lines with the Cohen's Kappa Coefficient score of 0.84

High Sensitivity

Lung ultrasound has high sensitivity (94%) and specificity (92%) for counting B-lines to detect Acute Cardiogenic Pulmonary Edema (ACPE) ⁹

Bring innovation to the bedside and beyond

Tedious tasks slow down your interactions with patients.

Exo’s AI had been designed to accommodate your clinical practice in the most demanding settings, so you can keep moving.

Get started with Exo AI

  • 1.Gianluigi Savarese, Peter Moritz Becher, Lars H Lund, Petar Seferovic, Giuseppe M C Rosano, Andrew J S Coats, Global burden of heart failure: a comprehensive and updated review of epidemiology, Cardiovascular Research, Volume 118, Issue 17, December 2022, Pages 3272–3287, https://doi.org/10.1093/cvr/cvac013
  • 2.Biykem Bozkurt, Tariq Ahmad, Kevin M. Alexander, et. al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. Journal of Cardiac Failure. Volume 29, Issue 10, Pages 1412-1451. https://doi.org/10.1016/j.cardfail.2023.07.006
  • 3.Heidenreich PA, Fonarow GC, Opsha Y, Sandhu AT, Sweitzer NK, Warraich HJ; HFSA Scientific Statement Committee Members Chair. Economic Issues in Heart Failure in the United States. J Card Fail. 2022 Mar;28(3):453-466. doi: 10.1016/j.cardfail.2021.12.017. Epub 2022 Jan 24. PMID: 35085762; PMCID: PMC9031347
  • 4.Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014 Dec;11(4):329-37. doi: 10.11909/j.issn.1671-5411.2014.04.008. PMID: 25593582; PMCID: PMC4292097.
  • 5.Katherine A.A. Clark, Samuel W. Reinhardt, Fouad Chouairi, P. Elliott Miller, Bradley Kay, Michael Fuery, Avirup Guha, Tariq Ahmad, Nihar R. Desai, Trends in Heart Failure Hospitalizations in the US from 2008 to 2018, Journal of Cardiac Failure, Volume 28, Issue 2, 2022, Pages 171-180, ISSN 1071-9164, https://doi.org/10.1016 j.cardfail.2021.08.020.
  • 6.Nair R, Lak H, Hasan S, Gunasekaran D, Babar A, Gopalakrishna KV. Reducing All-cause 30-day Hospital Readmissions for Patients Presenting with Acute Heart Failure Exacerbations: A Quality Improvement Initiative. Cureus. 2020 Mar 25;12(3):e7420. doi: 10.7759/cureus.7420. PMID: 32351805; PMCID: PMC7186095.
  • 7.Hussein Tahanulqiwa, Jahanavi Ramakrishna, Abdullah Yesilyaprak, Anoopa Matthew, Ahmad Refai, Vesna Tegeltija. A Resident-led Initiative To Improve Heart Failure Readmission Rate By Targeting Factors Of Social Vulnerability. Journal of Cardiac Failure. Volume 30, Issue 1, Pages 142-143. doi: https://doi.org/10.1016 j.cardfail.2023.10.064
  • 8.Zohrabian A, Kapp JM, Simoes EJ. The economic case for US hospitals to revise their approach to heart failure readmission reduction. Annuals of Translational Medicine. 2018 Aug;6(15):298.
  • 9.Mohammad Al Deeb, Skye Barbic, Robin Featherstone, Jerrald Dankoff, David Barbic. Point-of-care Ultrasonography for the Diagnosis of Acute Cardiogenic Pulmonary Edema in Patients Presenting With Acute Dyspnea: A Systematic Review and Meta-analysis. Academic Emergency Medicine. Volume 21, Issue 8, August 2014, pages 843-852. https://doi.org/10.1111/acem.12435